IN THE CLAIMS

*A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.*

1. (Original) The present invention relates to compounds of formula I:




I

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:

$R_1$ and $R_2$ independently represent

hydrogen, $NR_5R_6$, $CR_7R_8R_9$, $C(R)_2OR_{14}$, $CH_2NHR_{14}$, $C(=O)R_{13}$, $C(=NOH)H$, $C(=NOR_{13})H$, $C(=NOR_{13})R_{13}$, $C(=NOH)R_{13}$, $C(=O)N(R_{13})_2$, $C(=NOH)N(R_{13})_2$, $NHC(=X_1)N(R_{13})_2$, $(C=NH)R_7$, $N(R_{13})C(=X_1)N(R_{13})_2$, $COOR_{13}$, $SO_2R_{14}$, $N(R_{13})SO_2R_{14}$, $N(R_{13})COR_{14}$, $(C_{1\text{-}6}alkyl)CN$, CN, $CH=C(R)_2$, $C(R_4)_2X_1SiR_{16}$, $(CH_2)_pOH$, $C(=O)CHR_{13}$, $C(=NR_{13})R_{13}$, $NR_{10}C(=X_1)R_{13}$; or $C_{5\text{-}10}$ heterocycle optionally substituted with 1-3 groups of $R_7$, which may be attached through either a carbon or a heteroatom;

A represents C (when --- is present), CH or N (when --- is not present);

--- represents a bond;

represents aryl or heteroaryl, ~~heterocycle, heterocyclyl or heterocyclic, provided that in the case of a heteroaryl, heterocycle, heterocyclyl or heterocyclic,~~ provided that in the case of a heteroaryl, a cyclopropyl is not attached to a nitrogen atom on the ring;

$R_x$ represents hydrogen or $C_{1-6}$ alkyl;

$R_3$ represents 

which is an optionally substituted aromatic heterocyclic group containing at least one nitrogen in the ring and which is attached through a bond on any N, and which is unsubstituted or contains 1 to 3 substituents of $R_7$

$R_4$ and $R_{4a}$ independently represent
hydrogen,
halogen,
$C_{1-6}$ alkoxy, or
$C_{1-6}$ alkyl

r and s independently are 1-3, with the provision that when $(R_{4a})_s$ and $(R_4)_r$ are attached to an Ar or HAr ring the sum of r and s is less than or equal to 4;

$R_5$ and $R_6$ independently represent
hydrogen, $C_{1-6}$ alkyl optionally substituted with 1-3 groups of halogen, CN, OH, $C_{1-6}$ alkoxy, amino, imino, hydroxyamino, alkoxyamino, $C_{1-6}$ acyloxy, $C_{1-6}$ alkylsulfenyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, aminosulfonyl, $C_{1-6}$ alkylaminosulfonyl, $C_{1-6}$ dialkylaminosulfonyl, 4-morpholinylsulfonyl, phenyl, pyridine, 5-isoxazolyl, ethylenyloxy, or ethynyl, said phenyl and pyridine optionally substituted with 1-3 halogen, CN, OH, $CF_3$, $C_{1-6}$ alkyl or $C_{1-6}$ alkoxy; $C_{1-6}$ acyl optionally substituted with 1-3 groups of halogen, OH, SH, $C_{1-6}$ alkoxy, naphthalenoxy, phenoxy, amino, $C_{1-6}$ acylamino, hydroxylamino, alkoxylamino, $C_{1-6}$ acyloxy, aralkyloxy, phenyl, pyridine, $C_{1-6}$ alkylcarbonyl, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, $C_{1-6}$ hydroxyacyloxy, $C_{1-6}$ alkylsulfenyl, phthalimido, maleimido, succinimido, said phenoxy, phenyl and pyridine optionally substituted with 1-3 groups of halo, OH, CN, $C_{1-6}$ alkoxy, amino, $C_{1-6}$ acylamino, $CF_3$ or $C_{1-6}$ alkyl;

$C_{1-6}$ alkylsulfonyl optionally substituted with 1-3 groups of halogen, OH, $C_{1-6}$ alkoxy, amino, hydroxylamino, alkoxylamino, $C_{1-6}$ acyloxy, or phenyl; said phenyl optionally substituted with 1-3 groups of halo, OH, $C_{1-6}$ alkoxy, amino, $C_{1-6}$ acylamino, $CF_3$ or $C_{1-6}$ alkyl; arylsulfonyl optionally substituted with 1-3 of halogen, $C_{1-6}$ alkoxy, OH or $C_{1-6}$ alkyl;

$C_{1-6}$ alkoxycarbonyl optionally substituted with 1-3 of halogen, OH, $C_{1-6}$ alkoxy, $C_{1-6}$ acyloxy, or phenyl, said phenyl optionally substituted with 1-3 groups of halo, OH, $C_{1-6}$ alkoxy, amino, $C_{1-6}$ acylamino, $CF_3$ or $C_{1-6}$ alkyl; aminocarbonyl, $C_{1-6}$ alkylaminocarbonyl or $C_{1-6}$ dialkylaminocarbonyl, said alkyl groups optionally substituted with 1-3 groups of halogen, OH, $C_{1-6}$ alkoxy or phenyl, five to six membered heterocycles optionally substituted with 1-3 groups of halogen, OH, CN, amino, $C_{1-6}$ acylamino, $C_{1-6}$ alkylsulfonylamino, $C_{1-6}$ alkoxycarbonylamino, $C_{1-6}$ alkoxy, $C_{1-6}$ acyloxy or $C_{1-6}$ alkyl, said alkyl optionally substituted with 1-3 groups of halogen, or $C_{1-6}$ alkoxy;

$C_{3-6}$ cycloalkylcarbonyl optionally substituted with 1-3 groups of halogen, OH, $C_{1-6}$ alkoxy or CN; benzoyl optionally substituted with 1-3 groups of halogen, OH, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $CF_3$, $C_{1-6}$ alkanoyl, amino or $C_{1-6}$ acylamino; pyrrolylcarbonyl optionally substituted with 1-3 of $C_{1-6}$ alkyl; $C_{1-2}$ acyloxyacetyl where the acyl is optionally substituted with amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, 4-morpholino, 4-aminophenyl, 4-(dialkylamino)phenyl, 4-(glycylamino)phenyl; or $R_5$ and $R_6$ taken together with any intervening atoms can form a 3 to 7 membered heterocyclic ring containing carbon atoms and 1-2 heteroatoms independently chosen from O, S, SO, $SO_2$, N, or $NR_8$;

$R_7$ represent

hydrogen, halogen, CN, $CO_2R$, $CON(R)_2$, CHO, $CH_2NHAc$, C(=NOR), OH, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, alkenyl, $(CH_2)_n$amino, $(CH_2)_nC1-6$ alkylamino, $C_{1-6}$ dialkylamino, hydroxylamino or $C_{1-2}$ alkoxyamino all of which can be optionally substituted on the nitrogen with $C_{1-6}$ acyl, $C_{1-6}$ alkylsulfonyl or $C_{1-6}$ alkoxycarbonyl, said acyl and alkylsulfonyl optionally substituted with 1-2 of halogen or OH;

$R_8$ and $R_9$ independently represents

H, CN,

$C_{1-6}$ alkyl optionally substituted with 1-3 halogen, CN, OH, $C_{1-6}$ alkoxy, $C_{1-6}$ acyloxy, or amino,

phenyl optionally substituted with 1-3 groups of halogen, OH, $C_{1-6}$ alkoxy; or

$R_7$ and $R_8$ taken together can form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, $SO_2$, NH, and $NR_8$;

$X_1$ represents O, S or $NR_{13}$, NCN, $NCO_2R_{16}$, or $NSO_2R_{14}$

$R_{10}$ represents hydrogen, $C_{1-6}$ alkyl or $CO_2R_{15}$;

Each $R_{13}$ represents independently hydrogen, $C_{1-6}$ alkyl, $C_{6-10}$ aryl, $NR_5R_6$, $SR_8$, $S(O)R_8$, $S(O)_2$ $R_8$, CN, OH, $C_{1-6}$ alkylS(O)R, $C_{1-6}$ alkoxycarbonyl, hydroxycarbonyl, $C_{1-6}$ acyl, $C_{3-7}$ membered carbon ring optionally interrupted with 1-4 heteroatoms chosen from O, S, SO, $SO_2$, NH and $NR_8$ where said $C_{1-6}$ alkyl, aryl or $C_{1-6}$ acyl groups may be independently substituted with 0-3 halogens, hydroxy, $N(R)_2$, $CO_2R$, $C_{6-10}$ aryl, C 5-10 heteroaryl, or $C_{1-6}$ alkoxy groups;

When two $R_{13}$ groups are attached to the same atom or two adjacent atoms they may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, $SO_2$, NH, and $NR_8$;

R represents hydrogen or $C_{1-6}$ alkyl;

$R_{14}$ represents amino, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, five to six membered heterocycles or phenyl, said phenyl and heterocycles optionally substituted with 1-3 group of halo, $C_{1-6}$ alkoxy, $C_{1-6}$ acylamino, or $C_{1-6}$ alkyl, hydroxy and/or amino, said amino and hydroxy optionally protected with an amino or hydroxy protecting group;

$R_{15}$ is $C_{1-6}$ alkyl or benzyl said benzyl optionally substituted with 1-3 groups of halo, OH, $C_{1-6}$ alkoxy, amino, $C_{1-6}$ acylamino, or $C_{1-6}$ alkyl;

$R_{16}$ is hydrogen, $C_{5-10}$heteroaryl, C $_{6-10}$aryl, said heteroaryl and aryl optionally substituted with 1-3 groups of $R_7$;

m, n, p and q represents 0-1.

2. (Original) A compound according to claim 1 wherein $R_1$ and $R_2$ independently represent H, $NR_5R_6$, CN, OH, $C(R)_2OR_{14}$, $NHC(=X1)N(R_{13})2$, $C(=NOH)N(R_{13})2$, $NR_{10}C(=X_1)R_{13}$ or $CR_7R_8R_9$.

3. (Original) A compound according to claim 2 wherein 

is phenyl, pyridine, pyrimidine, or piperidine.

4. (Original) A compound according to claim 3 wherein one of $R_1$ and $R_2$ is H and the other is $NR_5R_6$; H and the other is CN; or H and the other is $NR_{10}C(=X_1)R_{13}$.

5. (Original) A compound according to claim 4 wherein A is C, --- is present, and $Z=(O)_n$ where n=0; A is C, --- is not present and Z=H, OH or halogen or A is N, --- is not present and $Z=(O)_n$ where n=1.

6. (Original) A compound according to claim 5 wherein $R_3$ is 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, tetrazole, pyrazole, or imidazole, any of which may contain 1 to 3 substitutents of $R_7$.

7. (Original) A compound which is:

1-[5(R)-3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-[(t-butyldiphenylsilyl)oxy]methylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-[(t-butyldiphenylsilyl)oxy]methylbicyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-hydroxyoxymethylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[3-fluoro-4-[(1α,5α,6α)-6-hydroxyoxymethylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[(1α,5α,6α)-6-cyanobicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-cyanobicyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

or its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

8. (Original) A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier and optionally a in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.

9. (Original) A method of treating or preventing a bacterial infection in a mammalian patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 1.

10. (Original) A method of treating or preventing bacterial infection or an oxazolidinone-associated side effect by administering an effective amount of a compound of formula I of claim 1 and an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.

11. (Original) A method according to claim 10 for treating or preventing oxazolidinone-associated normocyctic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis, hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis by administering an effective amount of vitamin B2 to a patient in need thereof.